Vol. 23/ No. 4 | OncologyLive

Unprecedented Advances Fuel Progress in the Treatment of AL Amyloidosis

February 25, 2022


Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.

Taming the Wild West: the View From the FDA

February 22, 2022

Julia A. Beaver, MD discusses the need for greater collaboration among industry sponsors on diagnostics, regulatory submissions, and multinational clinical trials involving PD-1/PD-L1 immune checkpoint inhibitors.

Checkpoint Inhibitor Changes Take Hold: Approval Standards Stir Debate

February 16, 2022

the development of PD-1/PD-L1 immune checkpoint inhibitor therapy underwent a course correction in 2021, with the withdrawal of a range of indications due to study results that failed to reach thresholds for confirming clinical benefit.